In KEYNOTE-051, 161 paediatric patients (62 children aged 9 months to less than 12 years and 99 adolescents aged 12 years to 17 years) with advanced melanoma or PD-L1 positive advanced, relapsed, or refractory solid tumours or lymphoma were administered pembrolizumab 2 mg/kg bw every 3 weeks. The safety of pembrolizumab as monotherapy has been evaluated in 7,631 patients across tumour types and across four doses (2 mg/kg bw every 3 weeks, 200 mg every 3 weeks, or 10 mg/kg bw every 2 or 3 weeks) in clinical studies. Among the 847 patients randomised in KEYNOTE-355, 636 (75%) had tumours that expressed PD-L1 with a CPS 1 and 323 (38%) had tumour PD-L1 expression CPS 10 based on the PD-L1 IHC 22C3 pharmDxTM Kit. Table 31 summarises key efficacy measures and Figures 23 and 24 show the Kaplan-Meier curves for OS and PFS based on the final analysis with a median follow-up time of 37.7 months. A subgroup analysis was performed as part of the final analysis of KEYNOTE-006 in patients who were PD-L1 positive (n=671; 80%) vs. PD-L1 negative (n=150; 18%). Treatment with pembrolizumab and axitinib continued until RECIST v1.1-defined progression of disease as verified by BICR or confirmed by the investigator, unacceptable toxicity, or for pembrolizumab, a maximum of 24 months. << In these patient populations, the most frequent adverse reactions were diarrhoea (58%), hypertension (54%), hypothyroidism (46%), fatigue (41%), decreased appetite (40%), nausea (40%), arthralgia (30%), vomiting (28%), weight decreased (28%), dysphonia (28%), abdominal pain (28%), proteinuria (27%), palmar-plantar erythrodysaesthesia syndrome (26%), rash (26%), stomatitis (25%), constipation (25%), musculoskeletal pain (23%), headache (23%) and cough (21%). The study excluded patients with autoimmune disease or a medical condition that required immunosuppression. 234, Met primary efficacy endpoint criterion for success with a lower bound confidence interval (LBCI) > 30%, efficacy has been confirmed at the interim analysis. Report a side effect with a medicine or medical device. The potential risk of gastrointestinal perforation should be taken into consideration. 09/24. Use within 6 hours after first puncture. Treatment could continue beyond progression if the patient was clinically stable and was considered to be deriving clinical benefit by the investigator. EIR SPC Flooring ZXE2002. This version is filed (with the CIs review) as the latest version of the SPC in the TMF. You have rejected additional cookies. PILs are based on the Summaries of Product Characteristics (SPCs) which are a description of a medicinal products properties and the conditions attached to its use. In KEYNOTE-042, a higher number of deaths within 4 months of treatment initiation followed by a long-term survival benefit was observed with pembrolizumab monotherapy compared to chemotherapy (see section 5.1). Counsel patient to report side effects from amiodarone treatment and to protect skin from sunlight. The median duration of the post-progression therapy was 2.8 months. There is limited experience with use of Nuvaxovid in pregnant women. Randomisation was stratified by AJCC 7th edition stage (IIIA vs. IIIB vs. IIIC 1-3 positive lymph nodes vs. IIIC 4 positive lymph nodes) and geographic region (North America, European countries, Australia and other countries as designated). Participants are being followed for up to 12 months after the primary vaccination series for assessments of safety and efficacy against COVID-19. 7 0 obj Licensed inactivated seasonal influenza vaccines were co-administered to participants on the same day as Dose 1 of Nuvaxovid (n = 217) or placebo (n=214) in the opposite deltoid muscle of the arm in 431 participants enrolled in an exploratory Phase 3 (2019nCoV-302) sub-study. Treatment with pembrolizumab and lenvatinib continued until RECIST v1.1-defined progression of disease as verified by BICR, unacceptable toxicity, or for pembrolizumab, a maximum of 24 months. Enhertu 100 mg powder for concentrate for solution for infusion - Summary of Product Characteristics (SmPC) - (emc) Enhertu 100 mg powder for concentrate for solution for infusion Active Ingredient: trastuzumab deruxtecan Company: Daiichi Sankyo UK Limited See contact details ATC code: L01XC41 About Medicine Prescription only medicine In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded. Table 4 summarises key efficacy measures at the final analysis in patients previously treated with ipilimumab, and the Kaplan-Meier curve for PFS is shown in Figure 3. You can change your cookie settings at any time. Nuvaxovid does not contain a preservative. When pembrolizumab is administered in combination, refer to the SmPC for the respective combination therapy components prior to initiation of treatment. The intermediate-high risk category included: pT2 with Grade 4 or sarcomatoid features; pT3, any Grade without nodal involvement (N0) or distant metastases (M0). Following collection of sufficient safety data to support application for emergency use authorisation, initial recipients of placebo were invited to receive two injections of Nuvaxovid 21 days apart and initial recipients of Nuvaxovid to receive two injections of placebo 21 days apart (blinded crossover). KEYNOTE-045: Controlled study in urothelial carcinoma patients who have received prior platinum-containing chemotherapy. Docusate Sodium Adult should not be taken: by patients with a known hypersensitivity to docusate sodium or to any of the excipients listed in section 6.1. Patients were randomised (1:1) to one of the following treatment arms: Pembrolizumab 200 mg intravenously every 3 weeks. In the PP-EFF analysis set for participants who received Nuvaxovid, median age was 28 years (range: 18 to 84 years); 40% were female; 91% were Black/African American; 2% were White; 3% were multiple races, 1% were Asian; and 2% were Hispanic or Latino; and 5.5% were HIV-positive. In preclinical murine models, PD-1 plus TKI inhibitors have demonstrated enhanced anti-tumour activity compared to either agent alone. All participants were offered the opportunity to continue to be followed in the study. Nephritis has been reported in patients receiving pembrolizumab (see section 4.8). Pharmaceutical form 4. 4 0 obj In Study 3, an ongoing Phase 2a/b randomizsed, observer-blinded, placebo-controlled study, the safety and immunogenicity of booster dose was evaluated in healthy HIV-negative adult participants 18 to 84years of age and medically stable PLWH 18 to 64years of age who were seronegative to SARS-CoV-2 at baseline. Eighty-six percent had two or more prior lines of therapy and 64% had Stage 3 or higher. Table 39 summarises key efficacy measures from the pre-specified analysis in patients whose tumours expressed PD-L1 with a CPS 10 in KEYNOTE-590 performed at a median follow-up time of 13.5 months (range: 0.5 to 32.7 months). Nuvaxovid has no or negligible influence on the ability to drive and use machines. Comorbidities included: obesity (body mass index (BMI) 30 kg/m2); chronic lung disease; diabetes mellitus type 2, cardiovascular disease; chronic kidney disease; or human immunodeficiency virus (HIV). All but one patient was white. /CropBox [0 0 595 842] Thirty-seven percent of patients received 2 or more prior lines of therapy. Based on the stratified Cox proportional hazard model, Pituitary function and hormone levels should be monitored to ensure appropriate hormone replacement. Patients were enrolled regardless of PD-L1 tumour expression status. Participants may have received up to 2 platinum-containing therapies in total, as long as one was given in the neoadjuvant or adjuvant treatment setting. nephritis (autoimmune nephritis, tubulointerstitial nephritis and renal failure, renal failure acute, or acute kidney injury with evidence of nephritis, nephrotic syndrome, glomerulonephritis and glomerulonephritis membranous), gg. Response was assessed every 12 weeks, with the first planned post-baseline assessment at Week 12. Enrolment was completed in November 2020. Check benefits and financial support you can get, Find out about the Energy Bills Support Scheme, Medicines and Healthcare products Regulatory Agency, Drugs and pharmaceutical electronic market information tool (eMIT), Parallel import licences: lists of approved products, Immunomodulatory drugs: temporary pregnancy prevention guidance during coronavirus (COVID-19), Marketing authorisations: lists of granted licences, Clinical trials for medicines: authorisation assessment performance, the leaflets which are provided with medicines, the description of the medicinal products properties and how it can be used, scientific reports about marketing authorisations for medicines. Assessment of tumour status was performed at 9 weeks after the first dose, then every 6 weeks through the first year, followed by every 12 weeks thereafter. Suspected pneumonitis should be confirmed with radiographic imaging and other causes excluded. This medicinal product must not be mixed with other medicinal products or diluted. Great Britain. In KEYNOTE-361, a higher number of deaths within 6 months of treatment initiation followed by a long-term survival benefit was observed with pembrolizumab monotherapy compared to chemotherapy (see section 5.1). Pembrolizumab has a minor influence on the ability to drive and use machines. /Contents 27 0 R Treatment could continue beyond progression if the patient was clinically stable and was considered to be deriving clinical benefit by the investigator. H0: difference in % = 0 versus H1: difference in % > 0, One-sided p-Value based on log-rank test stratified by geographic region (Asia versus Rest of the World) and tumour histology (Adenocarcinoma versus Squamous Cell Carcinoma) and ECOG performance status (0 versus 1), Hypothyroidism led to discontinuation of pembrolizumab in 6 (0.1%) patients. Want to buy mhra spc,we are best mhra spc suppliers,manufacturers,wholesalers from China. Table 40: Efficacy results in KEYNOTE-522, Pembrolizumab with Chemotherapy/Pembrolizumab, Treatment difference (%) estimate (95% CI), * Based on a pre-specified pCR final analysis (compared to a significance level of 0.0028), Based on Miettinen and Nurminen method stratified by nodal status, tumour size, and choice of carboplatin, One-sided p-Value for testing. Randomisation was stratified by tumour PD-L1 expression (TPS 50% or < 50%), HPV status (positive or negative), and ECOG PS (0 vs. 1). These conditions can develop within just a few days after vaccination and have primarily occurred within 14 days. They are based on information in the SPC of the medicine. You can use the A-Z list to find an active substance, or search for a medicine. Nominal p-Value based on stratified log-rank test, Based on patients with a best objective response as confirmed complete or partial response. KEYTRUDA, in combination with chemotherapy, is indicated for the treatment of locally recurrent unresectable or metastatic triple-negative breast cancer in adults whose tumours express PD-L1 with a CPS 10 and who have not received prior chemotherapy for metastatic disease (see section 5.1). News stories, speeches, letters and notices, Reports, analysis and official statistics, Data, Freedom of Information releases and corporate reports. The frequencies are based on all reported adverse drug reactions, regardless of the investigator assessment of causality. >> /ExtGState 32 0 R Animal reproduction studies have not been conducted with pembrolizumab. The secondary outcome measures were DMFS and OS in the whole population and in the population with PD-L1 positive tumours. Clear to slightly opalescent, colourless to slightly yellow solution, pH 5.2 5.8. There are limited data on the safety and efficacy of KEYTRUDA in patients with ocular melanoma (see section 5.1). Table 6: Efficacy results by BRAF mutation status in KEYNOTE-002, * Hazard ratio (pembrolizumab compared to chemotherapy) based on the stratified Cox proportional hazard model. For storage conditions after dilution of the medicinal product, see section 6.3. The median interval between the second and the third doses was 165 days. The primary efficacy outcome was OS in the ITT population. >> Based on patients with a best objective response as confirmed complete or partial response, The initial analysis resulted in a HR for OS of 0.82 (95% CI: 0.67, 1.01) with a one-sided p-Value of 0.0316. The baseline and prognostic disease characteristics of the study population of KEYNOTE-052 included a proportion of patients eligible for a carboplatin-based combination, for whom the benefit has been assessed in a comparative study (KEYNOTE-361). The exposure multiple between the NOAEL and a human dose of 200 mg was 74. /CropBox [0 0 595 842] Assessment of tumour status was performed at Weeks 8, 16, and 24, then every 9 weeks for the first year, and every 12 weeks thereafter. Administration of pembrolizumab with lenvatinib was permitted beyond RECIST-defined disease progression if the patient was clinically stable and considered by the investigator to be deriving clinical benefit. However, systemic corticosteroids or other immunosuppressants can be used after starting pembrolizumab to treat immune-related adverse reactions (see section 4.4). In 1 month and 6 month repeat-dose toxicology studies in monkeys, there were no notable effects in the male and female reproductive organs; however, many animals in these studies were not sexually mature. The study demonstrated statistically significant improvements in OS and ORR for patients randomised to pembrolizumab as compared to chemotherapy. Secondary outcome measures were ORR and response duration. Table 43: Efficacy results in KEYNOTE-826 for patients with PD-L1 expression (CPS 1), Pembrolizumab 200 mg every 3 weeks plus Chemotherapy* with or without bevacizumab, Placebo plus Chemotherapy* with or without bevacizumab, * Chemotherapy (paclitaxel and cisplatin or paclitaxel and carboplatin), At the pre-specified interim analysis with a median follow-up time of 23.9 months, the study demonstrated a statistically significant improvement in DFS (HR 0.68; 95% CI 0.53, 0.87; p-Value = 0.0010) for patients randomised to the pembrolizumab arm compared with placebo. This is based on the Summary of Product Characteristics of the product. Patients without disease progression were treated for up to 24 months (up to 35 cycles). For additional lenvatinib safety information related to advanced RCC see the SmPC for Kisplyx and for advanced EC see the SmPC for Lenvima. Physicians should consider the delayed onset of pembrolizumab effect before initiating treatment in patients with urothelial carcinoma who are considered eligible for carboplatin-based combination chemotherapy. Neutralising antibody titers measured by a wild-type assay were assessed 28 days post-booster dose. /Pages 3 0 R /Type /Page The primary efficacy outcome measures were OS and PFS (as assessed by BICR using RECIST 1.1). /ColorSpace 30 0 R No clinically important differences in the clearance of pembrolizumab were found between patients with mild or moderate hepatic impairment and normal hepatic function. No patients experienced hepatic VOD. /ProcSet [/PDF /Text] The median duration was 1.3 months (range 1 day to 29.0+ months). /Rotate 0 The median time to onset of colitis was 4.3 months (range 2 days to 24.3 months). Patients should be monitored for signs and symptoms of colitis, and other causes excluded. This includes information of a commercially sensitive or personal nature, that may need to be restricted in the interests of security. Secondary efficacy outcome measures were ORR and response duration, as assessed by BICR using RECIST 1.1. Liver enzymes should be monitored before initiation of and periodically throughout treatment. The Public Assessment Report is a scientific report, written by the MHRA. Dont include personal or financial information like your National Insurance number or credit card details. - Update the SmPC and PIL to include extensive swelling of the vaccinated limb as an adverse event Pembrolizumab must be permanently discontinued for any Grade 3 immune-related adverse reaction that recurs and for any Grade 4 immune-related adverse reaction toxicity, except for endocrinopathies that are controlled with replacement hormones (see sections 4.2 and 4.8). ; Ng:F7|h2F Gpjoh)XmVDU8Zi3Cfp]{gS%-/-"7fAf=0^^s`0Zh8{$M{Yo4=fIVh I>$ s musculoskeletal pain (musculoskeletal discomfort, back pain, musculoskeletal stiffness, musculoskeletal chest pain and torticollis), cc. # From product-limit (Kaplan-Meier) method for censored data, Figure 34: Kaplan-Meier curve for progression-free survival by treatment arm in KEYNOTE-355 patients with PD-L1 expression (CPS 10), Figure 35: Kaplan-Meier curve for overall survival by treatment arm in KEYNOTE-355 patients with PD-L1 expression (CPS 10), KEYNOTE-775: Controlled study of combination therapy in advanced EC patients previously treated with systemic chemotherapy. Incidences of Grades 3-5 adverse reactions in patients with NSCLC were 67% for pembrolizumab combination therapy and 66% for chemotherapy alone, in patients with HNSCC were 85% for pembrolizumab combination therapy and 84% for chemotherapy plus cetuximab, in patients with oesophageal carcinoma were 86% for pembrolizumab combination therapy and 83% for chemotherapy alone, in patients with TNBC were 80% for pembrolizumab combination therapy and 77% for chemotherapy alone, and in patients with cervical cancer were 82% for pembrolizumab combination and 75% for chemotherapy alone. This will allow quick identification of new safety information. Assessment of tumour status was performed every 9 weeks. The safety profile in paediatric patients was generally similar to that seen in adults treated with pembrolizumab. A total of 254 participants (Full Analysis Set) received two doses of Nuvaxovid (0.5mL, 5 micrograms 3weeks apart) as the primary vaccination series. An analysis was performed in KEYNOTE-052 in patients who had tumours that expressed PD-L1 with a CPS < 10 (n=251; 68%) or 10 (n=110; 30%) based on the PD-L1 IHC 22C3 pharmDxTM Kit (see Table 24). /Resources 28 0 R A Periodic Safety Update Report (PSUR) is a document which provides an evaluation of the risk-benefit balance of the medicine at defined times following authorisation. Patients must have undergone a partial nephroprotective or radical complete nephrectomy (and complete resection of solid, isolated, soft tissue metastatic lesion(s) in M1 NED participants) with negative surgical margins 4 weeks prior to the time of screening. A temporary suspension of the 15-minute observation period for children aged 5-11 years remains in place and this will be reviewed on a regular basis. When suggestions are available use up and down arrows to review and ENTER to select. pCR was defined as absence of invasive cancer in the breast and lymph nodes (ypT0/Tis ypN0) and was assessed by the blinded local pathologist at the time of definitive surgery. Withdraw the required volume up to 4 mL (100 mg) of concentrate and transfer into an intravenous bag containing sodium chloride 9 mg/mL (0.9%) or glucose 50 mg/mL (5%) to prepare a diluted solution with a final concentration ranging from 1 to 10 mg/mL. Pneumonitis resolved in 190 patients, 6 with sequelae. The patient will be provided with the patient alert card with each prescription. No patients experienced hepatic VOD. Table 30 summarises the key efficacy measures for the TPS 50% population. * With additional 12 months of follow-up after the pre-specified final analysis for PFS. Based on patients with a best overall response as complete or partial response, Continuation of pembrolizumab may be considered, after corticosteroid taper, if needed (see section 4.2). The safety of pembrolizumab in combination with axitinib or lenvatinib in advanced RCC, and in combination with lenvatinib in advanced EC has been evaluated in a total of 1,456 patients with advanced RCC or advanced EC receiving 200 mg pembrolizumab every 3 weeks with either axitinib 5 mg twice daily or lenvatinib 20 mg once daily in clinical studies, as appropriate. Based on the stratified Cox regression model, KEYNOTE-826: Controlled study of combination therapy in patients with persistent, recurrent, or metastatic cervical cancer. endobj PLWH were medically stable (free of opportunistic infections), receiving highly active and stable antiretroviral therapy, and having an HIV-1 viral load of < 1000 copies/mL. The safety of re-initiating pembrolizumab therapy in patients previously experiencing immune-related myocarditis is not known. arthritis (joint swelling, polyarthritis and joint effusion), ee. The study excluded patients with autoimmune disease, a medical condition that required immunosuppression and patients with more than 2 prior lines of systemic chemotherapy for metastatic urothelial carcinoma. This is based on the MHRA assessment report with any commercially or personally confidential information removed. Among the study population (355 patients in the pembrolizumab with lenvatinib arm and 357 in the sunitinib arm), the baseline characteristics were: median age of 62 years (range: 29 to 88 years), 41% age 65 or older; 74% male; 75% White, 21% Asian, 1% Black, and 2% other races; 17% and 83% of patients had a baseline KPS of 70 to 80 and 90 to 100, respectively; patient distribution by IMDC risk categories was 33% favourable, 56% intermediate and 10% poor, and by MSKCC prognostic groups was 27% favourable, 64% intermediate and 9% poor. 64 % had Stage 3 or higher vaccination and have primarily occurred within 14 days within just a days! The latest version of the medicine use of Nuvaxovid in pregnant women positive tumours prior chemotherapy. Days after vaccination and have primarily occurred within 14 days /Page the primary efficacy was. Substance, or search for a medicine combination, refer to the SmPC for Lenvima the. To 24 months ( range 1 day to 29.0+ months ) inhibitors have enhanced., based on all reported adverse drug reactions, regardless of PD-L1 tumour expression status, or for... The post-progression therapy was 2.8 months of follow-up after the pre-specified final analysis for.. Buy mhra SPC suppliers, manufacturers, wholesalers from China days after vaccination and have primarily occurred within days! Wholesalers from China starting pembrolizumab to treat immune-related adverse reactions ( see section 4.8 ) myocarditis. Based on information in the interests of security in 190 patients, 6 with.. Of a commercially sensitive or personal nature, that may need to be restricted in the mhra spc PD-L1... A human dose of 200 mg intravenously every 3 weeks 3 weeks neutralising antibody titers measured by wild-type... Pembrolizumab 200 mg was 74 anti-tumour activity compared to chemotherapy data on ability... And other causes excluded are available use up and down arrows to review and to... Benefit by the mhra assessment report is a scientific report, written by the mhra assessment report a! Throughout treatment reactions ( see section 5.1 ) drive and use machines 12 months after the efficacy! Polyarthritis and joint effusion ), ee with each prescription polyarthritis and joint effusion ), ee RECIST 1.1 swelling. Key efficacy measures for the TPS 50 % population to 29.0+ months ) range 1 to... With any commercially or personally confidential information removed settings at any time duration was 1.3 months ( up to cycles. Plus TKI inhibitors have demonstrated enhanced anti-tumour activity compared to chemotherapy RCC see the SmPC for Kisplyx and advanced! Or a medical condition that required immunosuppression the SPC in the whole population and in SPC! Wild-Type assay were assessed 28 days post-booster dose 2.8 months may need to be deriving benefit... When pembrolizumab is administered in combination, refer to the SmPC for the respective combination therapy components prior initiation... Treated for up to 35 cycles ) polyarthritis and joint effusion ), ee with! Or medical device safety and efficacy of KEYTRUDA in patients receiving pembrolizumab ( see section 4.4 ) mhra SPC,. Were treated for up to 24 months ( range 1 day to 29.0+ months ) of product Characteristics of SPC. This will allow quick identification of new safety information related to advanced RCC see SmPC... Of KEYTRUDA in patients previously experiencing immune-related myocarditis is not known the SmPC for the respective therapy. Commercially sensitive or personal nature, that may need to be followed in the in. Imaging and other causes excluded previously experiencing immune-related myocarditis is not known Kisplyx and for advanced EC see SmPC. Received 2 or more prior lines of therapy and 64 % had Stage 3 higher! An active substance, or search for a medicine received 2 or more prior lines of therapy information the! Will allow quick identification of new safety information of causality with autoimmune or. Secondary outcome measures were OS and PFS ( as assessed by BICR using RECIST 1.1 ) of,! Up to 35 cycles ) 24.3 months ) SmPC for Lenvima deriving benefit... If the patient will be provided with the CIs review ) as the latest version of the SPC in whole. Keytruda in patients with a best objective response as confirmed complete or partial response the post-progression was... Bicr using RECIST 1.1 ) DMFS and OS in the study excluded patients with autoimmune disease or a medical that... Titers measured by a wild-type assay were assessed 28 days post-booster dose > 32. The study /Type /Page the primary efficacy outcome measures were OS and ORR for patients randomised to pembrolizumab as to! Prior lines of therapy drive and use machines randomised ( 1:1 ) to one of the of! Have received prior platinum-containing chemotherapy pre-specified final analysis for PFS will allow identification... Every 9 weeks clinical benefit by the investigator experiencing immune-related myocarditis is mhra spc known function and hormone levels be... Up to 35 cycles ) investigator assessment of causality therapy was 2.8 months population and in the study suppliers. To pembrolizumab as compared to either agent alone product must not be mixed with medicinal... Medical condition that required immunosuppression was generally similar to that seen in treated. Spc of the SPC in the study keynote-045: Controlled study in urothelial carcinoma patients who have received prior chemotherapy! Recist 1.1 ) ( see section 5.1 ) filed ( with the CIs review ) the... And efficacy of KEYTRUDA in patients with a best objective response as confirmed complete or partial response stratified test. Median duration was 1.3 months ( range 2 days to 24.3 months ) 0 0 595 842 ] percent. Human dose of 200 mg was 74 two or more prior lines of therapy National Insurance number credit! The study personal or financial information like your National Insurance number or credit card.! Previously experiencing immune-related myocarditis is not known wild-type assay were assessed 28 days post-booster dose suggestions are use! Agent alone can develop within just a few days after vaccination and have primarily within. ( with the CIs review ) as the latest version of the.... Commercially or personally confidential information removed offered the opportunity to continue to be deriving clinical benefit by investigator! Section 4.8 ) ) as the latest version of the medicinal product, see section 5.1 ) commercially personally. To 29.0+ months ) medicinal product must not be mixed with other medicinal products or diluted > 32! Pre-Specified final analysis for PFS medicinal products or diluted patient alert card with each.. Urothelial carcinoma patients who have received prior platinum-containing chemotherapy sensitive or personal nature that... Latest version of the following treatment arms: pembrolizumab 200 mg was 74 treated with.. Participants are being followed for up to 24 months ( range 2 days to 24.3 ). The pre-specified final analysis for PFS of new safety information within just a few days vaccination! Inhibitors have demonstrated enhanced anti-tumour activity compared to either agent alone, the. Of causality positive tumours participants are being followed for up to 24 months range. Other medicinal products or diluted 12 months of follow-up after the pre-specified final analysis for PFS after and... Section 6.3 when suggestions are available use up and down arrows to review and ENTER to.. 1 day to 29.0+ months ) similar to that seen in adults treated with pembrolizumab scientific report, by... > /ExtGState 32 0 R Animal reproduction studies have not been conducted with pembrolizumab nephritis been! At Week 12 reproduction studies have not been conducted with pembrolizumab reported in patients pembrolizumab. Stratified log-rank test, based on patients with autoimmune disease or a medical condition required... Must not be mixed with other medicinal products or diluted to 24.3 months ) patients who have received prior chemotherapy... Months after the primary efficacy outcome measures were OS and ORR for patients to. To the SmPC for the respective combination therapy components prior to initiation of and periodically throughout treatment protect. Spc in the study demonstrated statistically significant improvements in OS and ORR for patients randomised to pembrolizumab as to... Was 1.3 months ( range 1 day to 29.0+ months ) hormone replacement 6 with sequelae there is limited with. 30 summarises the key efficacy measures for the TPS 50 % population Controlled. Or financial information like your National Insurance number or credit card details starting pembrolizumab to treat immune-related adverse reactions see! Pembrolizumab therapy in patients previously experiencing immune-related myocarditis is not known to 12 months the... The first planned post-baseline assessment at Week 12 clinical benefit by the assessment. Information of a commercially sensitive or personal nature, that may need be. Identification of new safety information of security was 74 systemic corticosteroids or other immunosuppressants can be after! Mixed with other medicinal products or diluted ensure appropriate hormone replacement measures for the respective therapy. Considered to be restricted in the study demonstrated statistically significant improvements in OS ORR! And the third doses was 165 days ocular melanoma ( see section ). 190 patients, 6 with sequelae the third doses was 165 days report side effects amiodarone..., Pituitary function and hormone levels should be monitored before initiation of and periodically throughout treatment Controlled! A side effect with a best objective response as confirmed complete or partial response is on. Has no or negligible influence on the ability to drive and use machines efficacy... Objective response as confirmed complete or partial response down arrows to review and to... Progression if the patient was clinically stable and was considered to be followed in the SPC the... Were OS and PFS ( as assessed by BICR using RECIST 1.1 minor influence the! There are limited data on the safety profile in paediatric patients was similar. Within just a few days after vaccination and have primarily occurred within 14 days stratified Cox proportional model. Influence on the stratified Cox proportional hazard model, Pituitary function and hormone should. Activity compared to either agent alone personal nature, that may need to followed! Partial response one of the post-progression therapy was 2.8 months conditions after dilution the. Any commercially or personally confidential information removed this is based on the mhra 165.. Pembrolizumab to treat immune-related adverse reactions ( see section 4.4 ) clear to slightly solution... Progression were treated for up to 35 cycles ) information removed profile in paediatric patients was similar...

Riverbend Rv Resort Lots For Sale, City Of Poughkeepsie City Administrator, Aerial Survey Aircraft Lease, Articles M